PT1673473E - Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias - Google Patents
Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias Download PDFInfo
- Publication number
- PT1673473E PT1673473E PT04765831T PT04765831T PT1673473E PT 1673473 E PT1673473 E PT 1673473E PT 04765831 T PT04765831 T PT 04765831T PT 04765831 T PT04765831 T PT 04765831T PT 1673473 E PT1673473 E PT 1673473E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- efficacy
- inflammatory disease
- genetic polymorphisms
- associate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50897103P | 2003-10-06 | 2003-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1673473E true PT1673473E (pt) | 2011-09-19 |
Family
ID=34520002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT04765831T PT1673473E (pt) | 2003-10-06 | 2004-10-05 | Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070155772A1 (pt) |
EP (1) | EP1673473B1 (pt) |
JP (1) | JP2007507460A (pt) |
CN (1) | CN1890384A (pt) |
AT (1) | ATE515577T1 (pt) |
AU (1) | AU2004283235B2 (pt) |
BR (1) | BRPI0415302A (pt) |
CA (1) | CA2541138A1 (pt) |
ES (1) | ES2367566T3 (pt) |
MX (1) | MXPA06003828A (pt) |
PL (1) | PL1673473T3 (pt) |
PT (1) | PT1673473E (pt) |
WO (1) | WO2005040416A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
WO2012116081A2 (en) | 2011-02-22 | 2012-08-30 | The Procter & Gamble Company | Methods for identifying cosmetic agents for skin care compositions |
EP2691539B1 (en) | 2011-03-31 | 2018-04-25 | The Procter and Gamble Company | Methods for identifying and evaluating skin-active agents effective for treating dandruff |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
EP2831272B8 (en) | 2012-03-30 | 2018-11-21 | The Procter and Gamble Company | Method of identifying a skin-lightening agent |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
JP2015527630A (ja) | 2012-06-06 | 2015-09-17 | ザ プロクター アンド ギャンブルカンパニー | ヘア/頭皮ケア組成物向け化粧剤の同定システム及び方法 |
EP2885426B1 (en) | 2012-08-15 | 2020-10-07 | The Procter and Gamble Company | Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
ES2548793B1 (es) * | 2014-03-17 | 2016-07-07 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa | Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
EP3458466A4 (en) * | 2016-05-20 | 2020-03-04 | Cedars-Sinai Medical Center | DIAGNOSIS OF GENE-BASED INFLAMMATORY BOWEL DISEASE |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3888224T2 (de) * | 1987-04-24 | 1994-07-21 | Teijin Ltd | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
-
2004
- 2004-10-05 PT PT04765831T patent/PT1673473E/pt unknown
- 2004-10-05 ES ES04765831T patent/ES2367566T3/es active Active
- 2004-10-05 BR BRPI0415302-2A patent/BRPI0415302A/pt not_active IP Right Cessation
- 2004-10-05 JP JP2006530098A patent/JP2007507460A/ja active Pending
- 2004-10-05 US US10/574,770 patent/US20070155772A1/en not_active Abandoned
- 2004-10-05 CA CA002541138A patent/CA2541138A1/en not_active Abandoned
- 2004-10-05 WO PCT/EP2004/011124 patent/WO2005040416A1/en active IP Right Grant
- 2004-10-05 EP EP04765831A patent/EP1673473B1/en active Active
- 2004-10-05 MX MXPA06003828A patent/MXPA06003828A/es not_active Application Discontinuation
- 2004-10-05 PL PL04765831T patent/PL1673473T3/pl unknown
- 2004-10-05 AT AT04765831T patent/ATE515577T1/de active
- 2004-10-05 CN CNA2004800358001A patent/CN1890384A/zh active Pending
- 2004-10-05 AU AU2004283235A patent/AU2004283235B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2541138A1 (en) | 2005-05-06 |
AU2004283235B2 (en) | 2007-08-02 |
AU2004283235A1 (en) | 2005-05-06 |
EP1673473A1 (en) | 2006-06-28 |
JP2007507460A (ja) | 2007-03-29 |
ATE515577T1 (de) | 2011-07-15 |
WO2005040416A1 (en) | 2005-05-06 |
EP1673473B1 (en) | 2011-07-06 |
CN1890384A (zh) | 2007-01-03 |
PL1673473T3 (pl) | 2011-12-30 |
BRPI0415302A (pt) | 2006-12-05 |
ES2367566T3 (es) | 2011-11-04 |
MXPA06003828A (es) | 2006-06-14 |
US20070155772A1 (en) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1673473T3 (pl) | Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych | |
EP2423326A3 (en) | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | |
EP2631292A3 (en) | Human microRNAs and methods for inhibiting same | |
WO2004035803A3 (en) | Method and nucleic acids for the treatment of breast cell proliferative disorders | |
WO2005087953A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
WO2001090419A3 (en) | Methods for genetic analysis of dna to detect sequence variances | |
EP2639318A3 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
EA201100452A1 (ru) | Лечение воспалительных состояний | |
ATE394674T1 (de) | Funktionalisierte nanopartikel und verwendungsverfahren | |
PL1730315T3 (pl) | Polimorfizmy w genie NOD2/CARD15 | |
WO2008008553A3 (en) | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof | |
EA201270574A1 (ru) | Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний | |
WO2005112544A3 (en) | Leptin promoter polymorphisms and uses thereof | |
ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
EP3075865A3 (en) | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms | |
WO2008051511A3 (en) | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | |
WO2006099365A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
WO2007124157A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
WO2009046422A3 (en) | Polymorphic nucleic acids associated with colorectal cancer and uses thereof | |
WO2006133866A3 (en) | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients | |
CN104099329A (zh) | 一种与高血压易感性相关的基因位点及其检测方法 | |
GB2489180A (en) | Method of predicting capecitabine toxicity | |
EP1870470A3 (en) | Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant | |
EP1531184A3 (en) | Kit and method for genetic testing of bladder cancer | |
NZ588905A (en) | Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease |